Boston Scientific (BSX) has been the leader in sales of stents, those little mess tubes that keep arteries open. Recent studies show that the devices are more dangerous than most doctors had believed. That has hurt sales and the BSX shares.
Now Abbott (ABT) is taking a stent of its own (the Xience) to the FDA. Some data show it may be better than the flagship Boston Scientific product call Taxus. If further review bears this out, BSX is in for another beating.
A JP Morgan analyst was recently quoted by The Associated Press as saying "The data presented by Abbott does show that Xience is statistically superior to Taxus, which is the market leader."
BSX shares are down 2.5% today to $12.37. If the FDA loves the new Abbott product, the stock may go lower.
Douglas A. McIntyre
In 20 Years, I Haven’t Seen A Cash Back Card This Good
After two decades of reviewing financial products I haven’t seen anything like this. Credit card companies are at war, handing out free rewards and benefits to win the best customers.
A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges.
Our top pick today pays up to 5% cash back, a $200 bonus on top, and $0 annual fee. Click here to apply before they stop offering rewards this generous.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.